You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
西藏藥業(600211.SH):拉薩經開區新生產基地取得藥品生產許可證
格隆匯 02-16 16:59

格隆匯2月16日丨西藏藥業(600211.SH)公佈,公司於2022年2月15日收到西藏自治區藥品監督管理局頒發的《藥品生產許可證》。生產地址和生產範圍:拉薩市北京中路93號:塗膜劑,硬膠囊劑,顆粒劑;拉薩市經濟技術開發區A區廣州路3號:塗膜劑(含中藥前處理及提取)。

生產線名稱雪山金羅漢止痛塗膜劑生產線;年產能:1500萬瓶(20毫升);代表品種:雪山金羅漢止痛塗膜劑;所屬藥品註冊分類/適應症或功能主治:國家中藥三類/活血,消腫,止痛。用於急慢性扭挫傷,風濕性關節炎,類風濕性關節炎,痛風,肩周炎,骨質增生所致的肢體關節疼痛腫脹,以及神經性頭痛。

公司在拉薩經濟技術開發區的新生產基地取得《藥品生產許可證》,將有利於公司提高生產能力,更好的滿足市場需求,對公司未來生產經營將產生積極作用,對當期業績無重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account